Prostate-specific membrane antigen (PSMA)–targeted PET/CT has become a fundamental tool in the management of patients with prostate cancer, especially to rule out local recurrence after surgery or radiation. However, the assessment of the prostatic fossa is difficult due to the renal excretion of PSMA-targeted radionuclides. PET/CT studies using 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 of a 61-year-old man after radical prostatectomy are presented. This case illustrates that 18F-PSMA-1007 is an ideal radionuclide for the detection of local recurrence of prostate cancer and is superior to 68Ga-PSMA-11, especially in case of pelvic lesions.
From the Departments of *Nuclear Medicine,
†Clinical Radiology, and
‡Urology, University Hospital Münster, Münster, Germany.
Received for publication October 22, 2018; revision accepted February 5, 2019.
Conflicts of interest and sources of funding: The University of Münster received consulting fees from ABX GmbH, Radeberg, Germany for K.R. and M.B. None declared to all other authors.
Correspondence to: Robert Seifert, MD, Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, Bldg A1, 48149 Münster, Germany. E-mail: firstname.lastname@example.org.